Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55


Regulatory B cells as inhibitors of immune responses and inflammation.

Bouaziz JD, Yanaba K, Tedder TF.

Immunol Rev. 2008 Aug;224:201-14. doi: 10.1111/j.1600-065X.2008.00661.x. Review.


B-lymphocyte contributions to human autoimmune disease.

Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF.

Immunol Rev. 2008 Jun;223:284-99. doi: 10.1111/j.1600-065X.2008.00646.x. Review.


A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF.

Immunity. 2008 May;28(5):639-50. doi: 10.1016/j.immuni.2008.03.017.


B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.

Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, Tisch RM, Tedder TF.

J Immunol. 2008 Mar 1;180(5):2863-75.


B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group.

N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.


Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF.

J Immunol. 2008 Jan 1;180(1):361-71.


Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.

Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20878-83. Epub 2007 Dec 19.


LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.

Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, Wong WM, Wang L, Su H, Chu TH, Guo J, Zhang W, So KF, Pepinsky B, Shao Z, Graff C, Garber E, Jung V, Wu EX, Wu W.

Nat Med. 2007 Oct;13(10):1228-33. Epub 2007 Sep 30.


Development of psoriasis after B cell depletion with rituximab.

Dass S, Vital EM, Emery P.

Arthritis Rheum. 2007 Aug;56(8):2715-8.


B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity.

Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, Tedder TF.

J Immunol. 2007 Jul 15;179(2):1369-80.


Exacerbation of ulcerative colitis after rituximab salvage therapy.

Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF.

Inflamm Bowel Dis. 2007 Nov;13(11):1365-8.


Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.

Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S.

Blood. 2007 Oct 15;110(8):2924-30. Epub 2007 Jun 4.


B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Hayakawa I, Tedder TF, Zhuang Y.

Immunology. 2007 Sep;122(1):73-9. Epub 2007 Apr 30.


Fitness of cell-mediated immunity independent of repertoire diversity.

AbuAttieh M, Rebrovich M, Wettstein PJ, Vuk-Pavlovic Z, Limper AH, Platt JL, Cascalho M.

J Immunol. 2007 Mar 1;178(5):2950-60.


Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.

Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK.

J Clin Invest. 2006 Sep;116(9):2393-402.


Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.

Krishnamoorthy G, Lassmann H, Wekerle H, Holz A.

J Clin Invest. 2006 Sep;116(9):2385-92.


B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF.

Am J Pathol. 2006 Sep;169(3):954-66.


Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.

El Tal AK, Posner MR, Spigelman Z, Ahmed AR.

J Am Acad Dermatol. 2006 Sep;55(3):449-59. Review.


Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK.

Nature. 2006 May 11;441(7090):235-8. Epub 2006 Apr 30.


Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF.

J Exp Med. 2006 Mar 20;203(3):743-53. Epub 2006 Mar 6.

Supplemental Content

Support Center